Thursday, March 21, 2013
Researchers at The University of Alabama at Birmingham have
identified idiopathic pulmonary fibrosis as a repurposing opportunity for fasudil, a Rho
kinase inhibitor that Asahi Kasei Pharma Corp. markets
to treat aneurysm. The key observation was that the drug acts on a pathway that
converts biochemical or biomechanical stimuli into fibrogenic signals that
sustain myofibroblast activation and survival.1
Making it work
Baas, T. SciBX 6(11); doi:10.1038/scibx.2013.255 Published online
March 21, 2013
1. Zhou, Y. et al. J.
Clin. Invest.; published online Feb. 22, 2013; doi:10.1172/JCI66700 Contact:
Victor J. Thannickal, The University of Alabama at Birmingham, Birmingham, Ala.
Contact: Yong Zhou, same affiliation as above e-mail: email@example.com
2. Wynn, T.A. &
Ramalingam, T.R. Nat. Med. 18, 1028-1040 (2012)
3. Huang, X. et al. Am.
J. Respir. Cell Mol. Biol. 47, 340-348 (2012)
AND INSTITUTIONS MENTIONED
Amakem N.V., Diepenbeek, Belgium
Asahi Kasei Pharma Corp., Tokyo, Japan
Firestone Institute for Respiratory Health, Hamilton, Ontario, Canada
Genoa Pharmaceuticals Inc., San Diego, Calif.
InterMune Inc. (NASDAQ:ITMN), Brisbane, Calif.
McMaster University, Hamilton, Ontario, Canada
UAB Research Foundation, Birmingham, Ala.
The University of Alabama at Birmingham, Birmingham, Ala.